{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:08:48Z","timestamp":1788764928002,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.prp.2026.156643","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:05:33Z","timestamp":1786115133000},"page":"156643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Structure-guided discovery of small-molecule ICOS-ICOSL antagonists that remodel intratumoral immunity and enhance anti-PD\u20111 therapy in osteosarcoma"],"prefix":"10.1016","volume":"287","author":[{"given":"Xianwen","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixing","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2026.156643_bib1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","article-title":"Advances on immunotherapy for osteosarcoma","volume":"23","author":"Yu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156643_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104575","article-title":"Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: recent advancements","volume":"206","author":"Adewuyi","year":"2025","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"2","key":"10.1016\/j.prp.2026.156643_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/cancers14020360","article-title":"Metastatic progression of osteosarcomas: a review of current knowledge of environmental versus oncogenic drivers","volume":"14","author":"Odri","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.prp.2026.156643_bib4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156643_bib5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","article-title":"Immuno-genomic landscape of osteosarcoma","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156643_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: Revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"10.1016\/j.prp.2026.156643_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug. Resist. Updates"},{"issue":"11","key":"10.1016\/j.prp.2026.156643_bib8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156643_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","article-title":"Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study","volume":"119","author":"Le Cesne","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156643_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71467","article-title":"Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory System","volume":"15","author":"Nikanjam","year":"2026","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.prp.2026.156643_bib11","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.immuni.2025.06.001","article-title":"The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+ CD8+ T cells","volume":"58","author":"Humblin","year":"2025","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.prp.2026.156643_bib12","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1158\/0008-5472.CAN-19-3265","article-title":"ICOS is an indicator of T-cell\u2013mediated response to cancer immunotherapy","volume":"80","author":"Xiao","year":"2020","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.prp.2026.156643_bib13","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.4049\/jimmunol.180.5.2967","article-title":"Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression","volume":"180","author":"Strauss","year":"2008","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.prp.2026.156643_bib14","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1158\/2326-6066.CIR-20-0034","article-title":"An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression","volume":"8","author":"Sainson","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.prp.2026.156643_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell."},{"issue":"9","key":"10.1016\/j.prp.2026.156643_bib16","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1039\/D3MD00150D","article-title":"First-in-class small molecule inhibitors of ICOS\/ICOSL interaction as a novel class of immunomodulators","volume":"14","author":"Abdel-Rahman","year":"2023","journal-title":"RSC Med. Chem."},{"issue":"6781","key":"10.1016\/j.prp.2026.156643_bib17","doi-asserted-by":"crossref","first-page":"eads9530","DOI":"10.1126\/science.ads9530","article-title":"Deep contrastive learning enables genome-wide virtual screening","volume":"391","author":"Jia","year":"2026","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.prp.2026.156643_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101664","article-title":"Protocol to isolate and analyze mouse bone marrow derived dendritic cells (BMDC)","volume":"3","author":"Sauter","year":"2022","journal-title":"STAR Protoc."},{"issue":"1","key":"10.1016\/j.prp.2026.156643_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000544","article-title":"The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy","volume":"5","author":"Solinas","year":"2020","journal-title":"ESMO Open."},{"issue":"2","key":"10.1016\/j.prp.2026.156643_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14712598.2020.1693540","article-title":"Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy","volume":"20","author":"Amatore","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.prp.2026.156643_bib21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell. death & Dis."},{"issue":"9","key":"10.1016\/j.prp.2026.156643_bib22","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","article-title":"Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial","volume":"70","author":"Boye","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2026.156643_bib23","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1038\/s41467-020-18828-4","article-title":"Structural characterization of the ICOS\/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies","volume":"11","author":"Rujas","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.prp.2026.156643_bib24","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood.V96.8.2808","article-title":"Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS","volume":"96","author":"Wang","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.prp.2026.156643_bib25","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjh.17968","article-title":"Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment","volume":"196","author":"Boggio","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.prp.2026.156643_bib26","doi-asserted-by":"crossref","first-page":"35056","DOI":"10.1038\/srep35056","article-title":"Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival","volume":"6","author":"Tu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156643_bib27","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.3389\/fimmu.2020.02104","article-title":"ICOS(+) Tregs: A Functional Subset of Tregs in Immune Diseases","volume":"11","author":"Li","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.prp.2026.156643_bib28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4049\/jimmunol.2300154","article-title":"ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations","volume":"213","author":"Diamantopoulos","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.prp.2026.156643_bib29","article-title":"Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2026.156643_bib30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<418::AID-IJC21>3.0.CO;2-5","article-title":"Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung","volume":"76","author":"Asai","year":"1998","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2026.156643_bib31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ijc.34008","article-title":"Lung fibrosis is a novel therapeutic target to suppress lung metastasis of osteosarcoma","volume":"151","author":"Yui","year":"2022","journal-title":"Int. J. Cancer"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:33:55Z","timestamp":1788762835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"alternative-id":["S0344033826002967"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156643","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided discovery of small-molecule ICOS-ICOSL antagonists that remodel intratumoral immunity and enhance anti-PD\u20111 therapy in osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156643"}}